CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 ...

The development of pharmaceutical treatments is difficult -- clinicians and researchers know a certain drug can regulate particular functions, but they might not know how it actually works.

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, ...

PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker ...

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

CAMBRIDGE, Mass., April 22, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, recently published a comprehensive ...